Safety and efficacy of delamanid in the treatment of multidrug-resistant tuberculosis (MDR-TB)

Clinical Medicine Insights: Therapeutics

Volumn 5, Issue , 2013, Pages 137-149

  Field, Stephen K ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Bedaquiline; Delamanid; Extensively drug resistant; Multidrug resistant; PA 824; Tuberculosis

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; AZD 5847; BEDAQUILINE; CAPREOMYCIN; CLOFAZIMINE; CYCLOSERINE; DELAMANID; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; SUTEZOLID; TERIZIDONE; THIOAMIDE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESISTANT TUBERCULOSIS; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVENING DOSAGE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HEALTH CARE COST; HUMAN; LATENT TUBERCULOSIS; LIVER TOXICITY; LUNG TUBERCULOSIS; MORNING DOSAGE; MULTIDRUG RESISTANT TUBERCULOSIS; NAUSEA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SHORT COURSE THERAPY; SYSTEMATIC REVIEW; TUBERCULOSIS; VOMITING;

EID: 84884757555     PISSN: 1179559X     EISSN: 1179559X     Source Type: Journal    
DOI: 10.4137/CMT.S11675     Document Type: Review

References (94)

1. World Health Organization. Global tuberculosis control 2012. Geneva WHO press, 2012. http://www.who.int/tb/publications/global_report/en/.
2. World Health Organization. Global tuberculosis control 2008. Surveillance, planning, financing. Geneva WHO 2008. http://www.who.int/tb/publications/global_report/2008/summary/en.
3. Blasi F, Dara M, van der Werf MJ, Migliori GB. Supporting TB clinicians managing difficult cases: the ERS/WHO consilium. Eur Respir J. 2013;41: 491-4.
4. WHO Global Tuberculosis Programme. An expanded DOTS framework for effective tuberculosis control: stop TB communicable diseases. World Health Organization: Geneva, 2002.
5. World Health Organization. Treatment of tuberculosis guidelines. 4th ed. Geneva WHO press, 2010.
6. Dalton T, Cegielski P, Akksilp S, etal. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet. 2012;380:1406-17.
7. World Health Organization. Guidelines for the programmic management of drug-resistant tuberculosis. Geneva: World Health Organization, 2008 http://whqlibdoc.who.int/publications/2008/9789241447581_eng.pdf.
8. World Health Organization. Guidelines for establishing DOTS-plus pilot projects for the management of multidrug-resistant tuberculosis (MDR-TB). Geneva: World Health Organization. 2000. http://whqlibdoc.int/hq/2000/WHO_CDS_TB_2000.279.pdf.
9. Bastian I, Rigouts L, van Deun A, Portaels F. Directly observed treatment, short-course strategy and multidrug-resistant tuberculosis: are any modifications required? Bull WHO. 2000;78:238-51.
10. Seaworth BJ, Field K, Flood J, etal. Interruptions in supplies of second-line antituberculosis drugs-United States, 2005-12. MMWR Morbid Mortal Wkly Rep. 2013;62(2):23-6.
11. Pooran A, Pieterson E, Davids M, Theron G, Dheda K. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? PLoS One. 2013;8(1):e54587.
12. Schnippel K, Rosen S, Shearer K, etal. Costs of inpatient treatment for multidrug-resistant tuberculosis in South Africa. Tropical Med Int Health. 2013;18(1):109-16. doi: 10.1111/tmi.12018.
13. Fitzpatrick C, Floyd K. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. Pharmacoeconomics. 2012;30(1):63-80.
14. Winston CA, Mitruka K. Treatment duration for patients with drug-resistant tuberculosis, United States. Emerg Infect Dis. 2012;18(7):1202-3.
15. Kurbatova EV, Gammino VM, Bayona J, etal. Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2012;16(10):1335-43.
16. Blondal K, Viiklepp P, Guomundsson LJ, Altraja A. Predictors of recurrence of multidrug-resistant and extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2012;16(9):1228-33.
17. Falzon D, Gandhi N, Migliori GB, etal. Resistance to fluoroquinolones and second-line injectable drugs: impact on MDR-TB outcomes. Eur Respir J. 2013;42(1):156-68.
18. Cavanaugh JS, Kazennyy BY, Nguyen ML, etal. Outcomes and follow-up of patients treated for multidrug-resistant tuberculosis in Orel, Russia, 2002-5. Int J Tuberc Lung Dis. 2012;16(8):1069-74.
19. Kurbatova EV, Taylor A, Gammino GM, etal. Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. Tuberculosis. 2012;92:397-403.
20. Althomsons SP, Cegielski JP. Impact of second-line drug resistance on tuberculosis treatment outcomes in the United States: MDR-TB is bad enough. In J Tuberc Lung Dis. 2012;16(10):1331-4.
21. Field SK, Fisher D, Jarand JM, Cowie RL. New treatment options for multidrug-resistant tuberculosis. Ther Adv Respir Dis. 2012;6(5):255-68. doi: 10.1177/1753465812452193.
22. Ahuja SD, Ashkin D, Avenado M, etal. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Medicine. 2012;9(8): e1001300.
23. Zar HJ, Udwadia ZF. Advances in tuberculosis 2011-2. Thorax. 2013;68: 283-7.
24. Padayatchi N, MacKenzie WR, Hirsch-Moverman Y, etal. Lessons from a randomized trial for multidrug-resistant tuberculosis. Int J Tuber Lung Dis. 2012;16(12):1582-7.
25. Mitnick CD, Franke MF, Rich ML, etal. Aggressive regimens for multidrug-resistant tuberculosis decrease all cause mortality. PLoS One. 2013;8(3): e58664.
26. Franke MF, Appleton SC, Mitnick CD, etal. Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence. Clin Infect Dis. 2013; 56(6):770-6.
27. Falzon D, Jaramillo E, Schunemann HJ, etal. WHO guidelines for the programmic management of drug-resistant tuberculosis. Eur Respir J. 2011;38:516-28.
28. Dooley KE, Mitnick CD, De Groote MA, etal. Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis. Clin Infect Dis. 2012;55:572-80.
29. Nunn P, Kibuga D, Gathua S. Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1seropositive patients treated for tuberculosis. Lancet. 1991;337:627-30.
30. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis, 2011 update. Geneva, WHO, 2011. Available from: http://whqlibdoc.int/publications/2011/9789241501583_eng.pdf.
31. Amaral L, Kristiansen JE. Phenothiazines: an alternative to conventional therapy for the initial management of suspected multidrug resistant tuberculosis. A call for studies. Int J Antimicrob Agents. 2000;14(2):173-6.
32. Amaral L, Martinds M, Viveiros M, Molnar J, Kristiansen JE. Promising therapy of XDR-TB/MDR-TB with thioridazine an inhibitor of bacterial efflux pumps. Curr Drug Targets. 2008;9(9):816-9.
33. Sharma S, Singh A. Phenothiazines as anti-tubercular agents: mechanistic insights and clinical implications. Expert Opin Investig Drugs. 2011. doi 10.1517/13543784.2011.628657.
34. Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis. New Engl J Med. 2012;368:745-55.
35. Seddon JA, Godfrey-Faussett P, Jacobs K, Ebrahim A, Hesseling AC, Schaaf HS. Hearing loss in patients on treatment for drug-resistant tuberculosis. Eur Respir J. 2012;40:1277-86.
36. Van den Boogaard J, Kibiki GS, Kisanga ER, Boeree MJ, Aarnoutse RE. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother. 2009;53(3):849-62.
37. Ginsburg AM. Drugs in development for tuberculosis. Drugs. 2010;70(17): 2201-14.
38. Burman WJ. Rip van Winkle wakes up: development of tuberculosis treatment in the 21st century. CID. 2010;50(Suppl 3):S165-72.
39. Villemagne B, Crauste C, Flipo M, Baulard AR, Deprez B, Willand N. Tuberculosis: the drug development pipeline at a glance. Eur J Med Chem. 2012;51:1-16.
40. Grosset JH, Singer TG, Bishai WR. New drugs for the treatment of tuberculosis: hope and reality. Int J Tuberc Lung Dis. 2012;16(8):1005-4.
41. Nunn A, Phillips PPJ, Abubaker I. Treatment of pulmonary tuberculosis. Curr Opin Pulm Med. 2013;19:273-9.
42. Zhang Y. Advances in the treatment of tuberculosis. Clin Pharmacol Ther. 2007;82:595-600.
43. Chaisson RE, Nuermberger EL. Confronting multidrug-resistant tuberculosis. New Eng J Med. 2012;366:2223-4.
44. Pontali E, Matteelli A, Migliori GB. Drug-resistant tuberculosis. Curr Opin Pulm Med. 2013;19:266-72.
45. Shi R, Sugawara I. Development of new anti-tuberculosis drug candidates. Tokhoku J Exp Med. 2010;221:97-106.
46. Horsburgh CR. Priorities for the treatment of latent tuberculosis infection in the United States. New Engl J Med. 2004;350:2060-7.
47. Stover CK, Warrener P, VanDevanter DR, etal. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature. 2000;405:962-6.
48. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database of Systematic Reviews (Online). 2000;(2):CD001363.
49. Gray DM, Zar H, Cotton M. Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV infected children. Cochrane Database of Systematic Reviews (Online). 2009;(1):CD006418.
50. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database of Systematic Reviews (Online). 2010;(1):CD000171.
51. Menzies D, Al Jahdali H, Al Otaibi B. Recent developments in treatment of latent tuberculosis infection. Indian J Med Res. Mar 2011;133(3):257-66.
52. Spyridis NP, Spyridis PG, Gelesme A, etal. The effectiveness of a 9-month regimen of isoniazid alone versus 3-and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis. 2007;45:715-22.
53. Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest. 2006;130:1712-7.
54. Page KR, Sifakis F, Montes de Oca R, etal. Improved adherence and less toxicity with rifampin versus isoniazid for improved adherence and less toxicity for treatment of latent tuberculosis. A retrospective study. Arch Intern Med. 2006;166:1863-70.
55. Center for Disease Control and Prevention. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003. MMWR Morb Mortal Wkly Rep. 2003;52(31):735-9.
56. Becerra MC, Appleton SC, Franke MF, etal. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet. 2011;377:147-52.
57. Grandjean L, Crossa A, Gilman RH, etal. Tuberculosis in household contacts of multidrug-resistant tuberculosis patients. Int J Tuberc Lung Dis. 2011;15(9):1164-9.
58. European Centre for Disease Prevention and Control. Management of contacts of MDR TB and XDR TB. Stockholm:ECDC;2012. http://www.ecdc.europa.eu/en/publications/publications/201203-guidance-mdr-tb-contacts.pdf.
59. Schaaf HS, Gie RP, Kennedy M, Beyers N, Hesseling PB, Donald PR. Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics. 2002;109(5):765-1.
60. Denholm JT, Leslie DE, Jenkin GA, etal. Long-term follow-up of contacts exposed to multidrug-resistant tuberculosis in Victoria, Australia, 1995-2010. Int J Tuberc Lung Dis. 2012;16(10):1320-5.
61. Attamna A, Chemtob D, Attamna S, etal. Risk of tuberculosis in close contacts of patients with multidrug resistant tuberculosis: a nationwide cohort. Thorax. 2009;64(3):271.
62. Kritski AL, Marques MJ, Rabahi MF, etal. Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 1996;153(1):331-5.
63. Ma Z, Lienhardt C, McIlleron H, Nunn A, Wang X. Global tuberculosis drug development pipeline: the need and the reality. Lancet. 2010;375:2100-9.
64. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333695.htm.
65. Cohen J. Approval of novel TB drug celebrated-with restraint. Science. 3013;339:130.
66. Safety and efficacy trial of delamanid for 6months in patients with multidrug resistant tuberculosis. http://clinicaltrials.gov/show/NCT01424670.
67. Mukherjee T, Boshoff H. Nitroimidazoles for the treatment of TB: past, present, and future. Future Med Chem. 2011;3:1427-54.
68. Showalter HDH, Denny WA. A roadmap for drug discovery and its translation to small molecule agents in clinical development for tuberculosis treatment. Tuberculosis. 2008;88(Suppl 1):S3-17.
69. Stover CK, Warrener P, VanDevanter DR, etal. A small molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature. 2000; 405:962-6.
70. Sasaki H, Haroguchi Y, Itotani M, etal. Synthesis and antituberculosis activity of a novel seires of optically active 6-nitro-2,3-dihydroimidazo [2,1-b] oxazoles. J Med Chem. 2006;49:7854-60.
71. Anonymous. OPC-67683. Tuberculosis Edinburgh. 2008;88(2):132-3.
72. Brennan PJ, Nikaido H. The envelope of mycobacteria. Annu Rev Biochem. 1995;64:29-63.
73. Glickman MS, Jacobs WR. Microbial pathogenesis of Mycobacterium tuberculosis: dawn of a discipline. Cell. 2001;104:477-85.
74. Abubakar I, Zignol M, Falzon D, et al. Tuberculosis. 2013:5. Drug-resistant tuberculosis: time for visionary political leadership. Lancet 2013, published online Mar 24, 2013 http://dx.doi.org/10.1016/S1473-3099(13)70030-6.
75. Singh R, Manjunatha U, Boshoff HIM, etal. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science. 2008;322: 1392-5.
76. Matsumoto M, Hashizume H, Tomishige T, etal. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Medicine. 2006;3:e466.
77. Manjunatha U, Boshoff HIM, Barry CE. The mechanism of action of PA-824. Commun Integr Biol. 2009;2:215-8.
78. Mitchison D, Davies G. The chemotherapy of tuberculosis: past, present, and future. Int J Tuberc Lung Dis. 2012;16(6):724-32.
79. Gurumurthy M, Mukherjee T, Dowd CS, etal. Substrate specificity of the deazaflavin-dependent nitroreductase (Ddn) from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles. FEBS J. 2012;279(1):113-25.
80. Hurdle JG, Lee RB, Budha NR, etal. A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. J Antimicrobial Chemother. 2008;62:1037-45.
81. Shi R, Sugawara I. Development of new anti-tuberculosis drug candidates. Tokhoku J Exp Med. 2010;221:97-106.
82. Lounis N, Gevers T, van den Berg J, Andries K. Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model. Antimicrob Agents Chemother. 2008;52:3568-72.
83. Diacon AH, Dawson R, Hanekom M, etal. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuber Lung Dis. 2011;15(7):949-54.
84. Gler MT, Skripconoka V, Sanchez-Garavito E, etal. Delamanid for multidrug-resistant pulmonary tuberculosis. New Engl J Med. 2012;366(23):2151-60.
85. Saliu OY, Crismale C, Schwander SK, Wallis RS. Bactericidal activity of OPC-67683 against drug-tolerant Mycobacterium tuberculosis et al. J Antimicrob Chemother. 2007;60:994-8.
86. Skripconoka V, Danilovits M, Pehme L, etal. Delamanid improves outcomes and reduces mortality for multidrug-resistant tuberculosis. ERJ express paper published Sep 27, 2012 as doi: 10.1183/09031936.00125812.
87. Zhang Q, Liu Y, Tang S, Sha W, Xial H. Clinical benefit of delamanid of multidrug-resistant tuberculosis patients in China. Cell Biochem Biophys. 2013. doi: 10.1007/s12013-0139589-5.
88. Diacon AH, Pym A, Groabusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. New Engl J Med. 2009;360(23): 2397-405.
89. Diacon AH, Donald PR, Pym A, etal. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother. 2012;56(6):3271-6.
90. Diacon AH, Dawson R, von Groote-Bidlingmaier F, etal. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide and moxifloxacin combinations: a randomized trial. Lancet. 2012;380:986-93.
91. Agrawal KC, Bears KB, Sehgal RK, Brown JN, Rist PE, Rupp WD. Potential radiosensitizing agents. Dinitroimidazoles. J Med Chem. 1979;22:583-6.
92. Nagarajan K, Shankar RG, Rajappa S, Shenoy ST, Costa-Pereira R. Nitroimidazoles XXI 2,3-dihydro-6-nitroimidazo [2,1-b] oxazoles with anti-tubercular activity. Eur J Med Chem. 1989;24:631-3.
93. Marx GE, Chan ED. Tuberculous meningitis: diagnosis and treatment overview. Tuberculosis Research and Treatment. 2011:Article 798764. doi: 10.1155/2011/798764.
94. Avorn J. Approval of a tuberculosis drug based on a paradoxical surrogate measure. JAMA. 2013;309(13):1349-50.